TW444020B - Nucleotide analogs - Google Patents
Nucleotide analogs Download PDFInfo
- Publication number
- TW444020B TW444020B TW086110757A TW86110757A TW444020B TW 444020 B TW444020 B TW 444020B TW 086110757 A TW086110757 A TW 086110757A TW 86110757 A TW86110757 A TW 86110757A TW 444020 B TW444020 B TW 444020B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- independently
- alkenyl
- alkynyl
- aryl
- Prior art date
Links
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract description 6
- -1 alkyenylaryl Chemical group 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 125000002877 alkyl aryl group Chemical group 0.000 abstract description 4
- 125000000304 alkynyl group Chemical group 0.000 abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 4
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- 125000001475 halogen functional group Chemical group 0.000 abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 4
- 125000005025 alkynylaryl group Chemical group 0.000 abstract description 3
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 3
- 230000000840 anti-viral effect Effects 0.000 abstract 3
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001540 azides Chemical group 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 125000000847 cytosin-1-yl group Chemical group [*]N1C(=O)N=C(N([H])[H])C([H])=C1[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68683896A | 1996-07-26 | 1996-07-26 | |
| US2270896P | 1996-07-26 | 1996-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW444020B true TW444020B (en) | 2001-07-01 |
Family
ID=26696272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086110757A TW444020B (en) | 1996-07-26 | 1997-08-21 | Nucleotide analogs |
| TW089123708A TW470748B (en) | 1996-07-26 | 1997-08-21 | Nucleotide analogs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089123708A TW470748B (en) | 1996-07-26 | 1997-08-21 | Nucleotide analogs |
Country Status (4)
| Country | Link |
|---|---|
| JP (6) | JP4033494B2 (enExample) |
| CA (1) | CA2261619C (enExample) |
| TW (2) | TW444020B (enExample) |
| WO (1) | WO1998004569A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998004569A1 (en) * | 1996-07-26 | 1998-02-05 | Gilead Sciences, Inc. | Nucleotide analogs |
| BR9811552A (pt) * | 1997-07-25 | 2000-08-29 | Gilead Sciences Inc | Composições de análogos de nucleotìdeos |
| DK1243590T3 (da) * | 1997-07-25 | 2005-07-25 | Gilead Sciences Inc | Nukleotid-analog sammensætning og syntesemetode |
| ATE288914T1 (de) * | 1997-07-25 | 2005-02-15 | Gilead Sciences Inc | Nukleotid-analog zusamensetzung und synthese verfahren |
| BR9911457A (pt) * | 1998-06-24 | 2001-12-11 | Univ Emory | Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv |
| AP1466A (en) * | 2000-07-21 | 2005-09-22 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. |
| UA80819C2 (en) | 2002-04-26 | 2007-11-12 | Gilead Sciences Inc | Phosphonate analogs of compounds inhibiting hiv proteases, pharmaceutical composition on their basis and their use |
| KR20090053867A (ko) | 2003-01-14 | 2009-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| AU2004233897A1 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
| EA011948B1 (ru) | 2003-06-16 | 2009-06-30 | Инститьют Оф Оргэник Кемистри Энд Байокемистри, Экэдеми Оф Сайэнс Оф Зе Чек Рипаблик | Фосфонатзамещенные пиримидиновые соединения (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции |
| US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| JP2007508845A (ja) | 2003-10-24 | 2007-04-12 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用化合物の同定のための方法および組成物 |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| EP1715871A1 (en) * | 2003-12-22 | 2006-11-02 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| ATE424400T1 (de) | 2003-12-22 | 2009-03-15 | Gilead Sciences Inc | 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv- antiviraler wirkung |
| TR201906416T4 (tr) | 2004-07-27 | 2019-05-21 | Gilead Sciences Inc | Hiv inhibitörü bileşiklerin fosfonat analogları. |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| JP5323476B2 (ja) * | 2005-06-13 | 2013-10-23 | 博瑞生物医葯技▲術▼（▲蘇▼州）有限公司 | ヌクレオチド類縁体プロドラッグおよびその製剤 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| JP5291700B2 (ja) | 2007-04-13 | 2013-09-18 | サザン リサーチ インスティテュート | 血管新生阻害薬及び使用方法 |
| AU2008253803A1 (en) * | 2007-05-22 | 2008-11-27 | Ultimorphix Technolgies B.V. | Tenofovir disoproxil hemi-fumaric acid Co-crystal |
| WO2009064174A1 (en) * | 2007-11-14 | 2009-05-22 | Ultimorphix Technologies B.V. | Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use |
| NZ588796A (en) * | 2008-04-25 | 2012-07-27 | Cipla Ltd | Crystalline form of tenofovir disoproxil and a process for its preparation |
| BRPI0915878A2 (pt) | 2008-07-08 | 2015-11-03 | Gilead Sciences Inc | sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende |
| CN102093422B (zh) | 2009-12-10 | 2015-02-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 无环核苷膦酸酯衍生物及其医药用途 |
| BR112013028698A8 (pt) * | 2011-05-10 | 2018-04-03 | Okapi Sciences Nv | Compostos para uso no tratamento de infecções retrovirais em felinos |
| AU2012296622C1 (en) | 2011-08-16 | 2017-02-16 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
| CN103626802A (zh) * | 2012-08-23 | 2014-03-12 | 重庆药友制药有限责任公司 | 一种制备替诺福韦的新方法 |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| JP2015536940A (ja) | 2012-10-29 | 2015-12-24 | シプラ・リミテッド | 抗ウイルス性ホスホネート類似体及びその製造方法 |
| EP2860185A1 (en) | 2013-10-09 | 2015-04-15 | Zentiva, k.s. | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof |
| EP2860184B1 (en) | 2013-10-09 | 2018-08-29 | Zentiva, k.s. | Dihydrogenphosphate salt of Tenofovir disoproxil |
| TWI660965B (zh) * | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| CN107805202A (zh) * | 2017-12-01 | 2018-03-16 | 内蒙古圣氏化学股份有限公司 | 一种氯甲基异丙基碳酸酯连续化反应装置及方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84477A (en) * | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
| ES2118069T3 (es) * | 1990-09-14 | 1998-09-16 | Acad Of Science Czech Republic | Profarmacos de fosfonatos. |
| GB9026164D0 (en) * | 1990-12-01 | 1991-01-16 | Beecham Group Plc | Pharmaceuticals |
| WO1995007920A1 (en) * | 1993-09-17 | 1995-03-23 | Gilead Sciences, Inc. | Nucleotide analogs |
| WO1998004569A1 (en) * | 1996-07-26 | 1998-02-05 | Gilead Sciences, Inc. | Nucleotide analogs |
-
1997
- 1997-07-25 WO PCT/US1997/013244 patent/WO1998004569A1/en not_active Ceased
- 1997-07-25 CA CA002261619A patent/CA2261619C/en not_active Expired - Lifetime
- 1997-07-25 JP JP50831898A patent/JP4033494B2/ja not_active Expired - Lifetime
- 1997-08-21 TW TW086110757A patent/TW444020B/zh not_active IP Right Cessation
- 1997-08-21 TW TW089123708A patent/TW470748B/zh not_active IP Right Cessation
-
2007
- 2007-07-09 JP JP2007180398A patent/JP2007297406A/ja not_active Withdrawn
-
2010
- 2010-10-15 JP JP2010233086A patent/JP2011016847A/ja not_active Withdrawn
-
2014
- 2014-04-15 JP JP2014083387A patent/JP2014159450A/ja not_active Withdrawn
-
2015
- 2015-04-28 JP JP2015091141A patent/JP2015164934A/ja not_active Withdrawn
-
2016
- 2016-10-31 JP JP2016212748A patent/JP2017031212A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2261619C (en) | 2006-05-23 |
| CA2261619A1 (en) | 1998-02-05 |
| WO1998004569A1 (en) | 1998-02-05 |
| JP2014159450A (ja) | 2014-09-04 |
| JP2011016847A (ja) | 2011-01-27 |
| TW470748B (en) | 2002-01-01 |
| JP2007297406A (ja) | 2007-11-15 |
| JP2015164934A (ja) | 2015-09-17 |
| JP4033494B2 (ja) | 2008-01-16 |
| JP2000515866A (ja) | 2000-11-28 |
| JP2017031212A (ja) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW444020B (en) | Nucleotide analogs | |
| JP5863789B2 (ja) | ピラゾール誘導体の製造方法 | |
| IE59713B1 (en) | Amino-thiazole and oxazole derivatives | |
| JP5805880B2 (ja) | １−（４−（４−（３，４−ジクロロ−２−フルオロフェニルアミノ）−７−メトキシキナゾリン−６−イルオキシ）ピペリジン−１−イル）−プロパ−２−エン−１−オン塩酸塩の製造方法および該方法で用いられる中間体 | |
| WO2006034583A1 (en) | Alkynyl based dervatives of benzophenone as non-nucleoside reverse transcriptase inhibitors | |
| CA2436665A1 (en) | Nucleic acid derivatives | |
| EP0520574A1 (en) | Thioxanthone derivatives | |
| HUP0400189A2 (hu) | Eljárás mikofenolát-mofetil előállítására | |
| US20090163712A1 (en) | Processes for preparing hiv reverse transcriptase inhibitors | |
| JP7109056B2 (ja) | Ｓ－ｉｃａリボシルホモシステインの製造方法 | |
| JPS5818346A (ja) | Ｎ−置換アクリルアミド及びメタクリルアミドの製造方法 | |
| KR830007510A (ko) | 심장질환 치료제의 제조방법 | |
| DE69526332T2 (de) | Indol-derivate | |
| CN104684921B (zh) | 用于暂时性生物缀合物合成的具有二芳基硫化物骨架的光可裂解的衔接物分子 | |
| EP0355085B1 (en) | A process for the preparation of 9-(hydroxyalkyl)-hypoxanthines | |
| US20250340585A1 (en) | Amidite monomer | |
| JP4245490B2 (ja) | ２−（ジクロロフェニル）−４−フェニルイミダゾール化合物 | |
| US2856405A (en) | Mecuration products of 1-(2-pyrimidyl)-3-allylurea | |
| Spychała | Convenient syntheses of N-methylthioamides: A migration of the H2S molecule in the thioamide-nitrile system | |
| JPH013178A (ja) | アミン誘導体の製造方法 | |
| Fu et al. | Design, synthesis and in vitro evaluation of l-amino acid esters prodrugs of acyclic nucleoside phosphonates as anti-HBV agent | |
| CN100415757C (zh) | 含有氮氧键的无环核苷膦酸酯类化合物、其制备方法及其应用 | |
| JPS6360969A (ja) | イミダゾ−ル誘導体の製造方法 | |
| JP4004082B2 (ja) | 環状ニトログアニジン誘導体の製造法 | |
| CA1067099A (en) | Process for the production of substituted benzyl cyanides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MK4A | Expiration of patent term of an invention patent |